August 27, 2022
PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed and developed a nanoengineered drug delivery platform to safely deliver highly potent drugs locoregionally, announced that Nature Communications published the results of the evaluation of efficacy and safety data collected using PRV111 on animal models of oral cancer and clinical trial in patients with oral cavity squamous cell carcinoma.
The article titled, "A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer" details the observed therapeutic benefit from topical delivery, via the PRV platform, of highly potent cisplatin directly into the lesions/tumors in animals as well as in human subjects suffering from oral cancer. The article features PRV111 (topical treatment) and PRV131 (intratumoral injectable). PRV111 is a mucoadhesive patch capable of topical delivery of nano-encapsulated cisplatin. The delivery platform enables local treatment for mucosal cancers and reduces the potential of systemic toxicity associated with systemic cisplatin and surgical morbidities such as impaired speech and swallowing and changes in appearance.
"We are very pleased to publish our work in a high-ranking peer-reviewed journal such as Nature Communications. This data highlights the promise of targeted and local chemotherapy treatment and validates the superior mechanism and design of the PRV Platform and its lead derivative PRV111. This data serves as a critical milestone for entering into a Phase 3 clinical trial for patients with Carcinoma in Situ of the oral cavity as well as a springboard for exploring the use of the platform in other mucosal cancers such as lung, cervical, vaginal, rectal, and anal cancers" said Manijeh Goldberg, PhD, founder and CEO of Privo. Dr. Goldberg is the first author of the article, which was published in collaboration with Dr. Nishant Agrawal, MD FACS, and Dr. Evgeny Izumchenko, PhD, at the University of Chicago, Dept of Surgery and Dept of Medicine, respectively.
Nature Communications is a peer-reviewed, open access, multidisciplinary journal dedicated to publishing high-quality research in all areas of biological, health, physical, chemical and Earth sciences.
About Privo Technologies, Inc.
Privo Technologies, Inc. ("Privo") is a phase 3 clinical-stage biopharmaceutical company committed to developing innovative therapeutics designed to eliminate cancers and prevent recurrence. Privo aims to provide better and more accessible treatment options to diverse patient populations around the world with the potential to transform standard of care for treating solid tumors.
Privo is headquartered in Peabody, a suburb of Boston Massachusetts. Privo's lead asset, PRV111 has been shown to be effective in patients with head and neck cancer in several hospitals across the US during a safety and efficacy Phase I/II clinical study, dramatically reducing tumor volume without any systemic toxicity.
For additional information on Privo Technologies, Inc. please visit www.privotechnologies.com.
Media Contact: communicationteam@privotechnologies.com
Read the full publication: A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer